GERN Geron Corporation
Legal ·
Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss.
The sales agreement pays TD Securities (USA) LLC up to 3.0% of gross proceeds. Geron's stock last sold at $1.65 on February 26, 2026, and the company's 2025 net loss was $83.5 million.
Geron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026.
The company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026.
Geron drew $125 million under a Pharmakon term loan and took $125 million from Royalty Pharma, in a quarter with a $26.4 million net loss. The release gives no royalty rates or loan interest rate.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $71.4 million | $103.7 million |
| Net income (loss) | -$83.5 million | -$174.6 million |
| Cash from operations | -$111.0 million | -$218.6 million |
| Cash and equivalents | $77.6 million | $79.0 million |
| Short-term investments | $327.6 million |
Our latest story on this, dated Aug 5, 2026: "Geron faces Rytelo securities class action and four derivative suits". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 2, 2026: "Geron files automatic shelf with $150,000,000 ATM prospectus via TD Cowen". The story links the filing or release it is based on. Read the story.
Geron Corporation trades under the ticker GERN on NASDAQ.
Geron Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:GON; LS:902213; LSE:0IV3; LSX:902213.
The SEC Central Index Key (CIK) for Geron Corporation is 886744. Its filings are on SEC EDGAR.
642,473,409 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Geron Corporation under United States.
Our directory classifies Geron Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Geron Corporation is US3741631036.
aibio.space lists Geron Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Geron Corporation reported a net loss of $83.5 million for the fiscal year ended Dec 31, 2025, and used $111.0 million of cash in operations, per its annual report to the SEC.
$71.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$62.6 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Geron, dated Aug 5, 2026: "Geron faces Rytelo securities class action and four derivative suits". Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss. Source.
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,2.02,2.03,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio